G-Zero Therapeutics funded under Qualifying Therapeutic Discovery Project
Cell signaling protein may hold key to blocking long-studied genetic mutation
In a study published this month in the Journal of Clinical Oncology, the results of a clinical trial of the drug bevacizumab to treat colon cancer in combination with the standard therapy found that the drug did not significantly increase disease-free survival in patients with stage II and stage III colon cancer.
$11.9 Million in awards to address cancer disparities
N.C. native John Isner and doubles partner Sam Querrey to host